Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Tax Provisions (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Tax Provisions for 9 consecutive years, with $58000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Tax Provisions fell 4.92% year-over-year to $58000.0, compared with a TTM value of $247000.0 through Sep 2025, down 79.92%, and an annual FY2024 reading of $224000.0, down 94.24% over the prior year.
  • Tax Provisions was $58000.0 for Q3 2025 at CytomX Therapeutics, down from $64000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $2.8 million in Q3 2023 and bottomed at $49000.0 in Q1 2024.
  • Average Tax Provisions over 3 years is $477777.8, with a median of $62000.0 recorded in 2025.
  • The sharpest move saw Tax Provisions plummeted 97.84% in 2024, then increased 26.53% in 2025.
  • Year by year, Tax Provisions stood at $1.1 million in 2023, then crashed by 94.11% to $63000.0 in 2024, then fell by 7.94% to $58000.0 in 2025.
  • Business Quant data shows Tax Provisions for CTMX at $58000.0 in Q3 2025, $64000.0 in Q2 2025, and $62000.0 in Q1 2025.